Clinical Trial Update: PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Paxlovid for prevention of long COVID in the community in Norway is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-acute Sequelae of Sars-cov-2 Infection

Drugs mentioned

• PAXLOVID (Nirmatrelvir and ritonavir)

Snippet

Sponsor: Haukeland University Hospital | Conditions: Post COVID-19 Condition, Unspecified, SARS-CoV2 Infection | Phase 3 | Status: ACTIVE_NOT_RECRUITING